Table 1.
Treatment | AST (U/L) | ALT (U/L) | GGT (U/L) | ALP (U/L) | Bilirubin (mg/dL) |
---|---|---|---|---|---|
Control | 91.71 ± 4.20 | 33.86 ± 2.30 | 3.48 ± 0.34 | 332.1 ± 10.06 | 0.54 ± 0.01 |
CCl4 | 296.0 ± 9.76** | 236.33 ± 7.85** | 11.71 ± 0.75** | 560.1 ± 10.28** | 2.42 ± 0.05** |
LSE-250 + CCl4 | 287.0 ± 8.00** | 233.50 ± 2.88** | 12.03 ± 0.41** | 522.0 ± 7.04**# | 2.11 ± 0.12**# |
LSE-500 + CCl4 | 291.8 ± 5.51** | 202.16 ± 4.17**# | 9.46 ± 0.24* | 516.5 ± 8.92**# | 2.06 ± 0.14**# |
Silymarin-10 + CCl4 | 196.6 ± 6.44*## | 107.46 ± 4.79*## | 5.10 ± 0.13## | 413.8 ± 9.20*## | 1.02 ± 0.06*## |
All values represent mean ± SEM. *P < 0.01 and **P < 0.001 verses control; #P < 0.05 and ##P < 0.01 versus CCl4 only group.